本文へ移動
cccskills
無料GitHub で公開

es-determine-hysterectomy-oophorectomy-necessity

Assesses whether hysterectomy and oophorectomy are medically necessary as part of gender-affirming surgery for transgender patients. Triggered when a patient is planning gender-affirming surgery and clinicians need to determine if total hysterectomy and oophorectomy should be included.

dromlakhani/MD2SKILL
インストール方法を見る

含まれるファイル（1）

  • SKILL.md2.4 KB

SKILL.md（原文）

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Determine medical necessity of hysterectomy and oophorectomy for gender-affirming surgery

STEP 1 — Gather Information

Collect sex assigned at birth, gender identity, planned gender-affirming procedures, current hormone regimen, fertility desires, personal/family history of reproductive tract cancer, discomfort with gynecologic care, and confirm presence of uterus and ovaries.

STEP 2 — Rule In / Rule Out

Determine if the patient possesses a uterus and ovaries (assigned female at birth). If no, hysterectomy/oophorectomy are not applicable; stop. If yes, proceed to evaluate necessity.

STEP 3 — Classify or Stratify

Stratify by fertility preservation desire and cancer risk tolerance: If patient desires future biological fertility, consider fertility‑sparing options or delay; if no fertility desire and patient reports gynecologic discomfort or seeks cancer risk reduction, classify as candidate for total hysterectomy and oophorectomy.

STEP 4 — Decide

For candidates, recommend inclusion of total hysterectomy and bilateral salpingo‑oophorectomy in the gender‑affirming surgical plan; for those desiring fertility, discuss oocyte/embryo cryopreservation and revisit decision after fertility goals are met.

Clinical Guardrails / Mimics / Pitfalls

Do not perform hysterectomy/oophorectomy based solely on gender identity without assessing individual risk and preference; avoid surgery in patients wishing to retain fertility without adequate preservation counseling; ensure informed consent regarding surgical menopause and lifelong hormone replacement if ovaries are removed.

Concrete Clinical Example

A 22‑year‑old transgender man assigned female at birth, on testosterone for 18 months, planning metoidioplasty, reports severe dysmenorrhea and desires no future pregnancy; after counseling, total hysterectomy with bilateral salpingo‑oophorectomy is added to his surgical plan.

Source: Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, DOI:10.1210/jc.2017-01658

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

ログインしてレビューを書く

同じリポジトリのスキル

概要と使いどころ

780g-pump-adjustment

無料

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-acth-stim-test-interpretation

無料

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-adrenal-crisis-treatment

無料

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-ai-education

無料

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-lt4-monitoring

無料

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-cortisol-cutoff-ai-diagnosis

無料

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する